About
Novel therapies against cardiometabolic diseases
Areas of Focus
Categories
Gene Therapy, RNA & Peptide TherapyVirginia, DC, DE & Maryland
Clinical Trials (4)
View allTotal Trials
4
As Lead Sponsor
4
As Collaborator
0
Total Enrollment
317
By Phase
PHASE2: 2PHASE3: 1PHASE1: 1
By Status
COMPLETED: 4
Clinical Trials Pipeline4 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2017
2018
2019
2020
2021
2022
Today
Hover over trial bars to see details
Recent Trials
NCT04164888Lead Sponsor
Phase 2a Study to Assess CIVI 007 in Patients on a Background of Statin Therapy
PHASE2Completed
49 participants
Started: Nov 11, 2019 · Completed: Nov 17, 2020
NCT04040322Lead Sponsor
Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3)
PHASE3Completed
198 participants
Started: Oct 14, 2019 · Completed: Jun 9, 2021
NCT03867097Lead Sponsor
Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 2)
PHASE2Completed
34 participants
Started: Mar 7, 2019 · Completed: Aug 6, 2019
NCT03427710Lead Sponsor
A First In Human Study to Assess CiVi007 in Subjects With an Elevated LDL-Cholesterol Level
PHASE1Completed
36 participants
Started: Feb 7, 2018 · Completed: Aug 18, 2020
Locations (1)
Headquarters
Chevy Chase, MD, United States
Map
Loading map...